149 related articles for article (PubMed ID: 35587830)
1. Diffuse glioma, not otherwise specified: imaging-based risk stratification achieves histomolecular-level prognostication.
Jang EB; Kim HS; Park JE; Park SY; Nam YK; Nam SJ; Kim YH; Kim JH
Eur Radiol; 2022 Nov; 32(11):7780-7788. PubMed ID: 35587830
[TBL] [Abstract][Full Text] [Related]
2. Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System.
Lee SJ; Park JE; Park SY; Kim YH; Hong CK; Kim JH; Kim HS
Korean J Radiol; 2023 Aug; 24(8):772-783. PubMed ID: 37500578
[TBL] [Abstract][Full Text] [Related]
3. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
4. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract][Full Text] [Related]
5. MR textural analysis on T
Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
[TBL] [Abstract][Full Text] [Related]
6. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
7. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
8. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
[TBL] [Abstract][Full Text] [Related]
10. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
[TBL] [Abstract][Full Text] [Related]
11. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
12. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
13.
Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
[TBL] [Abstract][Full Text] [Related]
14. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
17.
Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
[TBL] [Abstract][Full Text] [Related]
18. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
19. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
20. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
